Journal of Dali University ›› 2021, Vol. 6 ›› Issue (2): 20-24.DOI: 10. 3969 / j. issn. 2096-2266. 2021. 02. 004
Previous Articles Next Articles
Jiang Mingzhao, Miao Zhimin, Zhao Yingying, Lai Yong*
Received:
Revised:
Online:
Published:
Abstract: Objective: To investigate the effects of pyrazinamide on intestinal flora in mice. Methods: A solvent control group, a lowdose pyrazinamide group and a high-dose pyrazinamide group were set up with 10 mice in each group. Three groups of fresh feces were collected for 16S rRNA sequencing and analyzed by bioinformatics methods to determine the diversity of mouse intestinal flora. Results: At the phylum level, the low-dose group, the high-dose group, and the solvent control group are dominated by Bacteroidetes and Firmicutes, and their dominant flora accounted for 47.02%, 51.46%, 56.24%, 41.65%, 76.14% and 20.83%, respectively. At the genus level, the low-dose group is dominated by Bacteroides(8.42%)and Oscillospira(1.41%); the high-dose group is dominated by Lactobacillus(2.74%), Odoribacter(1.20%)and Bacteroides(1.14%); the solvent control group is mainly Prevotella(3.54%)and Bifidobacterium(1.81%). Compared with the solvent control group, the amino acid, energy and polysaccharide metabolism of the pyrazinamide group were significantly reduced(P < 0.05). Conclusion: Pyrazinamide can change the composition and metabolic function of intestinal flora.
Key words: pyrazinamide, intestinal flora, 16S rRNA
CLC Number:
R285.5
Jiang Mingzhao, Miao Zhimin, Zhao Yingying, Lai Yong. Effects of Different Concentrations of Pyrazinamide on Intestinal Microorganisms in Mice[J]. Journal of Dali University, 2021, 6(2): 20-24.
0 / / Recommend
Add to citation manager EndNote|Ris|BibTeX
URL: http://journal15.magtechjournal.com/Jwk_dlxyzk/EN/10. 3969 / j. issn. 2096-2266. 2021. 02. 004
http://journal15.magtechjournal.com/Jwk_dlxyzk/EN/Y2021/V6/I2/20
23
817. 〔2〕KHAN M T,REHAMAN A U,JUNAID M,et al. Insight in⁃ to Novel Clinical Mutants of RpsA-S324F,E325K,and G341R of Mycobacterium tuberculosis Associated with Pyra⁃ zinamide Resistance〔J〕. Comput Struct Biotechnol J,2018, 16:379-387. 〔3〕覃红娟,谭守勇,邝浩斌,等. 吡嗪酰胺与抗结核药物肝 损伤的相关性〔J〕. 实用医学杂志,2016,32(12):1948- 1951. 〔4〕唐外姣,周本杰. 肠道菌群失调:非酒精性脂肪肝病治疗 新靶点〔J〕. 世界华人消化杂志,2017,25(22):2000- 2006. 〔5〕陈竹,陈军华. 肠道菌群与结核病之间相关性的研究进 展〔J〕. 微生物与感染,2020,15(2):122-128. 〔6〕王丽凤. 益生菌L. plantarum P-8对肉鸡肠道菌群、肠道 免疫和生长性能影响的研究〔D〕. 呼和浩特:内蒙古农业 大学,2014. 〔7〕BEZIRTZOGLOU E,TSIOTSIAS A,WELLING G W. Mi⁃ crobiota Profile in Feces of Breast-and Formula-Fed New⁃ borns by Using Fluorescence in Situ Hybridization(FISH)
〔J〕. Anaerobe,2011,17(6):478-482. 〔8〕王玉瑛,张孝兴,汤淑斌,等. 小儿肠道外感染性疾病应 用抗生素后肠道菌群失调的临床分析〔J〕. 中国妇幼健 康研究,2016,27(9):1114-1116. 〔9〕李阳,巴雪,菅凌燕. 吡嗪酰胺药物不良反应临床使用的 分析〔J〕. 中国临床药理学杂志,2020,36(4):453-455. 〔10〕邱艳春. 抗结核药物性肝损伤152例临床分析和处理 体会〔J〕. 肝脏,2019,24(8):964-966. 〔11〕李园园. 益生菌补充对吡嗪酰胺致大鼠肝脏及肠黏膜 损伤影响研究〔D〕. 青岛:青岛大学,2018. 〔12〕杨松,郭建琼,严晓峰. 抗结核药物性肝损伤发生机制的 研究进展〔J〕. 中华结核和呼吸杂志,2019(5):378-381. 〔13〕雷中利,黄燕. 肠道菌群失调在肝癌发生、发展和预防、 治疗中的研究进展〔J〕. 肿瘤药学,2020,10(1):16-20. 〔14〕郭晓霞,胡娜,廉晓晓,等. 肝硬化患者肠道菌群失调的 特征及驱动因子分析〔J〕. 临床肝胆病杂志,2020,36 (7):1527-1533. 〔15〕栾雨婷,蔡文君,蒋轼丽,等. 乙型肝炎肝硬化患者伴或 不伴腹水对肠道菌群的影响〔J〕. 临床肝胆病杂志, 2020,36(7):1520-1526.